Please use this identifier to cite or link to this item: https://doi.org/10.21256/zhaw-3626
Full metadata record
DC FieldValueLanguage
dc.contributor.authorCorro Ramos, Isaac-
dc.contributor.authorLhachimi, Stefan K.-
dc.contributor.authorGerber-Grote, Andreas-
dc.contributor.authorAl, Maiwenn J.-
dc.date.accessioned2018-05-02T13:02:14Z-
dc.date.available2018-05-02T13:02:14Z-
dc.date.issued2016-
dc.identifier.issn0272-989Xde_CH
dc.identifier.issn1552-681Xde_CH
dc.identifier.urihttps://digitalcollection.zhaw.ch/handle/11475/5734-
dc.description.abstractBackground: The National Institute for Quality and Efficiency in Health Care (IQWiG) employs an efficiency frontier (EF) framework to facilitate setting maximum reimbursable prices for new interventions. Probabilistic sensitivity analysis (PSA) is used when yes/no reimbursement decisions are sought based on a fixed threshold. In the IQWiG framework, an additional layer of complexity arises as the EF itself may vary its shape in each PSA iteration, and thus the willingness-to-pay, indicated by the EF segments, may vary. Objectives: To explore the practical problems arising when, within the EF approach, maximum reimbursable prices for new interventions are sought through PSA. Methods: When the EF is varied in a PSA, cost recommendations for new interventions may be determined by the mean or the median of the distances between each intervention’s point estimate and each EF. Implications of using these metrics were explored in a simulation study based on the model used by IQWiG to assess the cost-effectiveness of 4 antidepressants. Results. Depending on the metric used, cost recommendations can be contradictory. Recommendations based on the mean can also be inconsistent. Results (median) suggested that costs of duloxetine, venlafaxine, mirtazapine, and bupropion should be decreased by €131, €29, €12, and €99, respectively. These recommendations were implemented and the analysis repeated. New results suggested keeping the costs as they were. The percentage of acceptable PSA outcomes increased 41% on average, and the uncertainty associated to the net health benefit was significantly reduced. Conclusions: The median of the distances between every intervention outcome and every EF is a good proxy for the cost recommendation that would be given should the EF be fixed. Adjusting costs according to the median increased the probability of acceptance and reduced the uncertainty around the net health benefit distribution, resulting in a reduced uncertainty for decision makers.de_CH
dc.language.isoende_CH
dc.publisherSagede_CH
dc.relation.ispartofMedical Decision Makingde_CH
dc.rightsLicence according to publishing contractde_CH
dc.subjectDecision analysisde_CH
dc.subjectDetailed methodology : probabilistic sensitivity analysisde_CH
dc.subjectSimulation methodsde_CH
dc.subjectAntidepressive Agentsde_CH
dc.subjectCost-Benefit Analysisde_CH
dc.subjectCosts and Cost Analysisde_CH
dc.subjectDecision Makingde_CH
dc.subjectGermanyde_CH
dc.subjectHumande_CH
dc.subjectModels, Econometricde_CH
dc.subjectModel, Statisticalde_CH
dc.subjectUncertaintyde_CH
dc.subject.ddc610: Medizin und Gesundheitde_CH
dc.subject.ddc658.4: Leitendes Managementde_CH
dc.titleCost recommendation under uncertainty in IQWiG’s efficiency frontier frameworkde_CH
dc.typeBeitrag in wissenschaftlicher Zeitschriftde_CH
dcterms.typeTextde_CH
zhaw.departementGesundheitde_CH
dc.identifier.doi10.21256/zhaw-3626-
dc.identifier.doi10.1177/0272989X16636856de_CH
zhaw.funding.euNode_CH
zhaw.issue2de_CH
zhaw.originated.zhawYesde_CH
zhaw.pages.end172de_CH
zhaw.pages.start162de_CH
zhaw.publication.statuspublishedVersionde_CH
zhaw.volume37de_CH
zhaw.publication.reviewPeer review (Publikation)de_CH
Appears in collections:Publikationen Gesundheit

Files in This Item:
File Description SizeFormat 
0272989x16636856.pdf1.07 MBAdobe PDFThumbnail
View/Open
Show simple item record
Corro Ramos, I., Lhachimi, S. K., Gerber-Grote, A., & Al, M. J. (2016). Cost recommendation under uncertainty in IQWiG’s efficiency frontier framework. Medical Decision Making, 37(2), 162–172. https://doi.org/10.21256/zhaw-3626
Corro Ramos, I. et al. (2016) ‘Cost recommendation under uncertainty in IQWiG’s efficiency frontier framework’, Medical Decision Making, 37(2), pp. 162–172. Available at: https://doi.org/10.21256/zhaw-3626.
I. Corro Ramos, S. K. Lhachimi, A. Gerber-Grote, and M. J. Al, “Cost recommendation under uncertainty in IQWiG’s efficiency frontier framework,” Medical Decision Making, vol. 37, no. 2, pp. 162–172, 2016, doi: 10.21256/zhaw-3626.
CORRO RAMOS, Isaac, Stefan K. LHACHIMI, Andreas GERBER-GROTE und Maiwenn J. AL, 2016. Cost recommendation under uncertainty in IQWiG’s efficiency frontier framework. Medical Decision Making. 2016. Bd. 37, Nr. 2, S. 162–172. DOI 10.21256/zhaw-3626
Corro Ramos, Isaac, Stefan K. Lhachimi, Andreas Gerber-Grote, and Maiwenn J. Al. 2016. “Cost Recommendation under Uncertainty in IQWiG’s Efficiency Frontier Framework.” Medical Decision Making 37 (2): 162–72. https://doi.org/10.21256/zhaw-3626.
Corro Ramos, Isaac, et al. “Cost Recommendation under Uncertainty in IQWiG’s Efficiency Frontier Framework.” Medical Decision Making, vol. 37, no. 2, 2016, pp. 162–72, https://doi.org/10.21256/zhaw-3626.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.